Shares of Lexicon Pharmaceuticals, Inc. (LXRX) said it received a regulatory feedback that clears a key hurdle for partnership discussions around sotagliflozin in heart failure.
Lexicon Pharmaceuticals said it received U.S. Food and Drug Administration regulatory feedback that the results of its SOLOIST and SCORED Phase 3 clinical studies can support a new drug application submission for an indication to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent visits for heart failure in adult patients with type 2 diabetes with either worsening heart failure or additional risk factors for heart failure.
https://www.nasdaq.com/articles/stock-alert%3A-lexicon-pharmaceuticals-surges-35-2021-01-14
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.